Your SlideShare is downloading. ×
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Seminiar 30-11-2013 Side effects treat opo short
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Seminiar 30-11-2013 Side effects treat opo short

119

Published on

Side effects treat opo short

Side effects treat opo short

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
119
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. n e Nevenwerkingen van medicaties bij fractuurpreventie: klinisch relevant? . r h . P s u e G Prof Piet Geusens, MD, PhD Reumatoloog Maastricht UMC & UHasselt
  • 2. n e Disclosure belangen spreker (potentiële) belangenverstrengeling s u e G Voor bijeenkomst mogelijk relevante relaties met bedrijven   Honorarium of andere (financiële) vergoeding Aandeelhouder Andere relatie, namelijk … . r h   . P Sponsoring of onderzoeksgeld Geen Geen  Pfizer, Abbott, Lilly, Amgen, MSD, Will, Roche  Pfizer, Abbott, Lilly, Amgen, MSD, UCB, Will, BMS, Novartis  Geen  NVT
  • 3. Nevenwerkingen in RCTs . r h . P s u e G n e
  • 4. n e . r h . P CALCIUM s u e G
  • 5. Bolland 2008 . P n e s u e G Boland 2010 Calcium treatment was associated with: • increased risk of myocardial infarction dietary calcium intake > 805 mg/day (HR 1.85, 1.28-2.67) • no increased risk in those with dietary calcium intake < 805mg/day (HR 0.98, 0.691.38) . r h BMJ 2008;336;262-266; BMJ 2010;341:c3691
  • 6. n e s u e G Participants 61 433 women (born between 1914 and 1948) followed-up for a median of 19 years (Michaelson, BMJ, 2013) . r h . P
  • 7. n e . r h . P s u e G RCT 1200 mg calcium vs placebo; women ≥ 70. Base-line dietary intake 950 mg calcium JBMR, Vol. 25, 2010, pp 2205–2211
  • 8. n e Adjusted dose-response association between daily calcium supplement intake and risk for cardiovascular death . r h . P s u e G Plos One 2013: e61037
  • 9. Medische behandeling: calcium en vitamine D s u e G – Optimalisatie van calcium inname: • Totaal: 1000-1200 mg calcium/dag – Vb: geen melkproducten . P – Vb: 1-2 zuivelporties/dag – Vb: 3-4 zuivelporties/dag . r h MUMC&UHasselt n e + 3-4 zuivelporties of 1000 mg calcium supplement + 1-2 zuivelporties of +500 mg calcium supplement geen aanpassing nodig 1 zuivelportie = 1 stevig glas melk 1 pot yoghurt 1 schel kaas
  • 10. n e . r h . P VITAMIN D s u e G
  • 11. Vitamin D supplements s u e G n e • Toxic dose: >10.000 IU/d • Annual oral 500,000 IU of cholecalciferol – 26% increased risk of fracture and a 15% increased risk of falling compared to placebo (Sanders, JAMA, 2010) . P • Oral cholecalciferol 150,000 IU/3-monthly – neither beneficial nor adverse effects on falls or physical function (Glendennig, JBMR, 2012) . r h
  • 12. Vitamin D supplements in patients with a recent fracture . r h . P n e s u e G Before CBO 2011 Loading dose according to baseline 25(OH)D 80% achieved >50 nmol/L After CBO 2011 Fixed dose of 800IU/d 80% achieved >50 nmol/L Shab-Bidar, European Journal of Endocrinology (2013) 169 597
  • 13. n e . r h . P s u e G A vitamin D3 dosage of 800 IU/d increased serum 25-(OH)D levels to greater than 50 nmol/L in 97.5% of women Gallagher, AIM, 2012
  • 14. Medische behandeling: calcium en vitamine D s u e G – Optimalisatie van calcium inname: • Totaal: 1000-1200 mg calcium/dag – Vb: geen melkproducten – Vb: 1-2 zuivelporties/dag . P – Vb: 3-4 zuivelporties/dag – Vitamine D: 800 E/dag • • • • n e + 3-4 zuivelporties of 1000 mg calcium supplement + 1-2 zuivelporties of +500 mg calcium supplement geen aanpassing nodig Bij osteoporose behandeling Bij mensen in verzorgingsinstelling Hoger indien nodig Na recente fractuur . r h MUMC&UHasselt 1 zuivelportie = 1 stevig glas melk 1 pot yoghurt 1 schel kaas
  • 15. n e . r h . P s u e G ANTIRESORPTIEVE MEDICATIES
  • 16. n e Selected bisphosphonate-associated adverse events of interest . r h . P s u e G Liwiecki, Drugs 2011; 71 (6): 791
  • 17. n e . r h . P s u e G BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW (ONJ, BONJ, BRONJ)
  • 18. n e Risk factors for bisphosphonate-associated osteonecrosis of the jaw . r h . P s u e G Khosla, J Bone Miner Res, 2007, 1479
  • 19. n e Differential diagnosis of osteonecrosis of the jaw in bisphosphonate-treated patients . r h . P s u e G Khosla, J Bone Miner Res, 2007, 1479
  • 20. ONJ in cancer patients n e s u e G • The incidence of bisphosphonate-associated ONJ is highest in patients with underlying malignancies • who receive high doses of iv bisphosphonates (e.g. zoledronic acid, 4mg iv every 3–4 wk) to decrease the risk of skeletal complications of malignancy • 1 and 10% may go on to develop ONJ . r h . P Khosla, JCEM, 2012
  • 21. Association between exposure to oral BPs and ONJ in osteoporosis . r h . P n e s u e G Italian record linkage claims database with a target population of 6 million over 55 years of age Incidence rate: 36.6 per 100,000 person-years Lapi, Osteoporos Int (2013) 24:697
  • 22. ONJ in osteoporosis . r h . P n e s u e G Solomon, Osteoporos Int (2013) 24:237
  • 23. ONJ in osteoporosis . r h . P n e s u e G Solomon, Osteoporos Int (2013) 24:237
  • 24. n e . r h . P s u e G ATYPICAL FEMUR FRACTURE
  • 25. AFF . r h . P n e s u e G Ng & Png, JBMR, 2013, online
  • 26. n e Definition of atypical femur fracture, requiring the presence of each of the listed major features s u e G Prodromes in >50% of cases Often bilateral . r h . P Shane, J Bone Miner Res 2010, 2267
  • 27. n e Case reports in the literature and reports in the FAERS database of bisphosphonate-associated atypical femoral fractures from January 1996 to September 2011 . r h . P s u e G Edwards, Bone Joint Surg Am. 2013;95:297-307
  • 28. n e . r h . P s u e G Edwards, Bone Joint Surg Am. 2013;95:297-307
  • 29. n e The risk of subtrochanteric and femoral shaft fractures in bisphosphonate users from large observational studies . r h . P s u e G Saleh, Orthop Clin N Am 44 (2013) 137–151
  • 30. n e . r h . P s u e G Prasarn, Clin Orthop Relat Res (2012) 470:2295–2301
  • 31. n e Randomeffects analysis of the studies for the association between bisphosphonate use and subtrochanteric, femoral shaft, and atypical femur fracture (AFF), . r h . P s u e G Gedmintas, JBMR, 2013, 1729
  • 32. n e Random effects analysis of the studies for the association between bisphosphonate use and subtrochanteric, femoral shaft, and atypical femur fracture (AFF), stratified by outcome definition . r h . P s u e G Gedmintas, JBMR, 2013, 1729
  • 33. n e Random effects analysis of the studies for the association between long‐term bisphosphonate use (5 years or greater) and subtrochanteric and femoral shaft fractures . r h . P s u e G Gedmintas, JBMR, 2013, 1729
  • 34. AFF Duration of BPs . r h . P n e s u e G Time to union Thompson, J Bone Joint Surg Br, 2012;94-B:385–90.
  • 35. Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women s u e G * . r h ST/D FN/intertroch . P 42 817 n e * 349 5587 204 2438 * 121 881 Park, JAMA, February 23, 2011—Vol 305, No. 8 783
  • 36. n e Bisphosphonate Use and Atypical Fractures of the Femoral Shaft (atypical subtrochanteric fractures, n=56) 80 70 60 50 40 30 20 . r h 10 0 0 Natyp 13 Nwomen 1437820 . P <1yr 3 15672 1--2yr 4 21406 s u e G >2yr 39 46233 HR N cases stop BPs <1yr 42 83311 1--2yr >2yr 1 3 70036 75583 Schilcher, N Engl J Med 2011;364:1728-37.
  • 37. Bone microarchitecture in AFF . r h . P n e s u e G Zanchetta, JBMR, 2013, online
  • 38. n e Microindentation values for the four groups of study subjects. (A) Total indentation distance (Total ID), age-adjusted statistical differences . r h . P s u e G Guerri, Journal of Bone and Mineral Research, Vol. 28, 2013, pp 162
  • 39. n e Reduction in bone scan uptake post-teriparatide treatment. Bone scintigraphy scans pre- and post-teriparatide treatment showing reduction in the intensity of isotope uptake (n=4). . r h . P s u e G Chiang, Bone 52 (2013) 360–365
  • 40. n e . r h . P s u e G BISFOSFONATEN EN SLOKDARM KANKER MUMC&UHasselt
  • 41. n e . r h MUMC&UHasselt . P s u e G Dixon, Nat. Rev. Rheumatol. 2011, 369
  • 42. n e . r h MUMC&UHasselt . P s u e G Dixon, Nat. Rev. Rheumatol. 2011, 369
  • 43. n e . r h . P s u e G DENOSUMAB AND INFECTIONS
  • 44. Serious adverse events of cellulitis and erysipelas and relationship to timing of administration . r h . P n e s u e G Watts, OI, 2012
  • 45. Denosumab vs. Placebo Infections . r h . P n e s u e G Watts, OI, 2012
  • 46. Denosumab 6 yrs . r h . P s u e G n e
  • 47. n e . r h . P s u e G FRACTUURHELING
  • 48. Fracture healing . r h . P n e s u e G Claes, NRR, 2012
  • 49. Fracture healing • Bisphosphonates – Increased callus s u e G • Denosumab (Adami, JBJS, 2012) . P – No delayed union • Teriparatide . r h – Positive effect? n e • NSAIDs (Geusens, Curr Opin Rh, 2013) – Avoid long-term use after recent fracture
  • 50. n e . r h . P s u e G ANABOLE MIDDELEN
  • 51. Teriparatide s u e G n e • In clinical trials the following reactions were reported at a ≥ 1% difference in frequency from placebo: . P – vertigo, nausea, pain in limb, dizziness, depression, dyspnoea . r h
  • 52. n e . r h . P s u e G STRONTIUM RANELAAT
  • 53. Strontium ranelate s u e G n e • Drug rash with eosinophilia and systemic symptoms (DRESS) (Cacoub, OI, 2012) – 1/24.000 (France) • DVT (Osborne, Drug Saf 2010) . P – Incidence: 6/1000 patient yrs • CV events (EMEA 2013) . r h – Protelos/Osseor should not be used in patients with current or past history of ischaemic heart disease (such as angina or a heart attack), peripheral arterial disease (obstruction of large blood vessels, often in the legs) or cerebrovascular disease (diseases affecting the blood vessels supplying the brain, such as stroke). – Protelos/Osseor should not be used in patients with hypertension (high blood pressure) that is not adequately controlled by treatment.
  • 54. n e Veiligheid s u e G • Bisfosfonaten (JCEM 2012:2272) – – – – Osteonecrose kaak Atypische femurfracturen Atriumfibrillatie Oesofagus carcinoom . P 0.001 – 0.1% 0,0005% - 0,2% associatie in één studie geen associatie • Denosumab (JCEM 2013:4483) . r h – Osteonecrose kaak – Atypische femurfracturen – Infecties / cellulitis 8 casus 2 casus 1,4 en <0,1%
  • 55. 63-year-old woman with: - rheumatoid arthritis for 30 years - diabetes for 3 years - alendronate 70mg weekly for 7 years . P 6 months . r h Baseline: Spinal compression fractures L3 and L4 T-score spine: -2.25 n e s u e G No mention of calcium and vitamin D intake or follow up strategy! J Clin Endocrinol Metab 98: E723–E726, 2013
  • 56. Follow up tijdens behandeling: gestructureerde monitoring Sterk aanbevolen Kan zinvol zijn Start therapie n e s u e G Gestructureerde klinische monitoring (min. na 3 maanden, nadien jaarlijks) Intolerantie . r h Non Compliance Niet-wervel fractuur na 1 jaar therapie . P Botmarkers Zo nodig andere medicatie of SC of IV Klinisch vermoeden van nieuwe wervelfractuur Bij twijfel/vragen RX DXA na 2-3 jaar Overleg Teriparatide (2de keuze: PTH), na 3de fractuur waaronder 2 wervelfracturen
  • 57. Conclusies n e s u e G • Gezien de zeer lage incidentie van ONJ en AFF versus de belangrijke fractuurreductie met bisfosfonaten en denosumab, is de risico/benefit verhouding duidelijk in het voordeel van behandeling van patiënten met een hoog fractuurrisico: . P – met een wervel of heupfractuur – of een BMD T-score <2.5 . r h • Of dit ook het geval is wanneer patiënten geselecteerd worden op basis van FRAX of Garvan, noodzaakt verder onderzoek

×